Nordimet (Methotrexate)

Methotrexate, the active ingredient in Nordimet, is an antimetabolite presented as an injection for subcutaneous use. It is employed to modify disease processes in rheumatoid arthritis, psoriasis, juvenile idiopathic arthritis, and certain malignancies such as acute lymphoblastic leukemia and non‑Hodgkin lymphoma.

GNH USA supplies Nordimet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory compliance, and reliable logistics for this essential therapy.

Methotrexate is used as a disease‑modifying antirheumatic drug (DMARD) and antimetabolite in several immune‑mediated and oncologic conditions. - Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriasis: improves skin lesions and reduces plaque formation. - Juvenile idiopathic arthritis: controls disease activity and prevents joint damage. - Acute lymphoblastic leukemia: interferes with malignant cell proliferation. - Non‑Hodgkin lymphoma: contributes to cytoreduction as part of combination therapy.

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Fatigue: general tiredness or weakness. - Oral ulcers: painful sores in the mouth. - Elevated liver enzymes: mild hepatic enzyme rise. - Low blood counts: mild leukopenia or anemia.

Serious or Rare Side Effects: - Severe liver toxicity: potential hepatitis or fibrosis. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Bone marrow suppression: profound pancytopenia. - Renal impairment: acute kidney injury. - Severe infection: opportunistic infections due to immunosuppression.

When prescribing methotrexate, clinicians should observe several safety precautions to minimize risk. - Pregnancy contraindication: avoid use in pregnancy (Category X) and ensure effective contraception. - Liver monitoring: perform baseline and periodic liver function tests. - Renal function: assess creatinine clearance before initiation and during therapy. - Hematologic surveillance: monitor complete blood count regularly. - Drug interactions: review concomitant medications that may increase toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several medicines that can alter its efficacy or increase toxicity.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase methotrexate toxicity. - Proton pump inhibitors (omeprazole, esomeprazole): can raise serum methotrexate levels. - Trimethoprim‑sulfamethoxazole: enhances myelosuppression risk.

Moderate Interactions (Monitor Closely): - Azathioprine or mycophenolate: additive immunosuppression. - Live vaccines: risk of infection due to immunosuppression. - Phenytoin or carbamazepine: may reduce methotrexate efficacy.